Manufacturer of Controlled Substances; Notice of Application, 75497 [2010-30351]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C 958(a); 21 USC 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DATED: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30338 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 29, 2010, and
published in the Federal Register on
April 16, 2010, 75 FR 20000, Lipomed,
Inc., One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances:
mstockstill on DSKH9S0YB1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N–Ethylamphetamine (1475) ........
Fenethylline (1503) .......................
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
(7390).
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4–Methyl-2,5dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-Nethylamphetamine (7404).
VerDate Mar<15>2010
16:09 Dec 02, 2010
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 223001
Schedule
Drug
3,4–
Methylenedioxymethamphetamine (7405).
4–Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N–Benzylpiperazine (7493) ..........
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
3–Methylfentanyl (9813) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
the basic classes of controlled
substances listed.
I
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Lipomed, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Lipomed, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
PO 00000
Frm 00047
Fmt 4703
75497
Sfmt 4703
[FR Doc. 2010–30334 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 29, 2010,
Siegfried (USA), Inc., 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Hydromorphinol (9301), a basic class of
controlled substance listed in schedule
I.
The company plans to manufacture
small quantities of the listed controlled
substance in bulk for distribution to its
customers for use as reference
standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 1, 2011.
Dated: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30351 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to 1301.33(a), Title 21 of the
Code of Federal Regulations (CFR), this
is notice that on September 13, 2010,
Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Page 75497]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30351]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 29, 2010, Siegfried
(USA), Inc., 33 Industrial Park Road, Pennsville, New Jersey 08070,
made application by letter to the Drug Enforcement Administration (DEA)
to be registered as a bulk manufacturer of Hydromorphinol (9301), a
basic class of controlled substance listed in schedule I.
The company plans to manufacture small quantities of the listed
controlled substance in bulk for distribution to its customers for use
as reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 1, 2011.
Dated: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-30351 Filed 12-2-10; 8:45 am]
BILLING CODE 4410-09-P
